Evaluation of different recall periods for the US National Cancer Institute's PRO-CTCAE

Clinical Trials

Volumn 14, Issue 3, 2017, Pages 255-263

  Mendoza, Tito R ^a   Dueck, Amylou C ^b   Bennett, Antonia V ^c   Mitchell, Sandra A ^d   Reeve, Bryce B ^c   Atkinson, Thomas M ^e   Li, Yuelin ^e   Castro, Kathleen M ^d   Denicoff, Andrea ^d   Rogak, Lauren J ^e   Piekarz, Richard L ^d   Cleeland, Charles S ^a   Sloan, Jeff A ^f   Schrag, Deborah ^g   Basch, Ethan ^c,e  

^a UNIVERSITY OF TEXAS   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f MAYO CLINIC   (United States)

^g DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

measurement properties; patient reported outcomes; PRO CTCAE; Recall period; symptomatic adverse events; validation

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGE; AGED; ANXIETY; ARTICLE; CANCER CENTER; CANCER PATIENT; CONSTIPATION; CORRELATION COEFFICIENT; DECREASED APPETITE; DRUG SURVEILLANCE PROGRAM; DYSPNEA; EFFECT SIZE; FATIGUE; FEMALE; HEALTH CARE FACILITY; HUMAN; INSOMNIA; LANGUAGE ABILITY; LOOSE FECES; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; MEDICAL TERMINOLOGY; MIDDLE AGED; MOUTH DISEASE; NAUSEA; NEUROPATHY; PAIN; PATIENT-REPORTED OUTCOME; PRIORITY JOURNAL; RECALL; SADNESS; SCORING SYSTEM; SEX RATIO; SIDE EFFECT; SYSTEMATIC ERROR; TIME; UNITED STATES; VOMITING; XEROSTOMIA; ADVERSE DRUG REACTION; CHEMORADIOTHERAPY; CLASSIFICATION; EVALUATION STUDY; NATIONAL HEALTH ORGANIZATION; NEOPLASM; SELF REPORT; STATISTICS AND NUMERICAL DATA; TIME FACTOR; YOUNG ADULT;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MALE; MENTAL RECALL; MIDDLE AGED; NATIONAL CANCER INSTITUTE (U.S.); NEOPLASMS; PATIENT REPORTED OUTCOME MEASURES; SELF REPORT; TIME FACTORS; UNITED STATES; YOUNG ADULT;

EID: 85019763992     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774517698645     Document Type: Article

References (18)

1. Basch E, Reeve BB, Mitchell SA, et al. Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst 2014; 106: dju244.
2. Hay JL, Atkinson TM, Reeve BB, et al.; NCI PRO-CTCAE Study Group. Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Qual Life Res 2014; 23: 257-269.
3. Broderick JE, Schwartz JE, Vikingstad G, et al. The accuracy of pain and fatigue items across different reporting periods. Pain 2008; 139: 146-157.
4. US Department of Health and Human Services, Food and Drug Administration. Guidance for industry: Patient-reported outcomes measures: use in medical product development to support labeling claims., 2009, http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf (. accessed 9 July 2015).
5. Stull DE, Leidy NK, Parasuraman B, et al. Optimal recall periods for patient-reported outcomes: challenges and potential solutions. Curr Med Res Opin 2009; 25: 929-942.
6. Gorin AA, Stone AA,. Recall biases and cognitive errors in retrospective self-reports: a call for momentary assessments. In: Baum A, Revenson T, Singer J, (eds) Handbook of health psychology. Mahwah, NJ: Erlbaum, 2001, pp. 405-413.
7. Bennett AV, Patrick DL, Lymp JF, et al. Comparison of 7-day and repeated 24-hour recall of symptoms of cystic fibrosis. J Cyst Fibros 2010; 9: 419-424.
8. Bennett AV, Patrick DL, Bushnell DM, et al. Comparison of 7-day and repeated 24-h recall of type 2 diabetes. Qual Life Res 2011; 20: 769-777.
9. Bennett AV, Amtmann D, Diehr P, et al. Comparison of 7-day recall and daily diary reports of COPD symptoms and impacts. Value Health 2012; 15: 466-474.
10. Broderick JE, Schneider S, Schwartz JE, et al. Interference with activities due to pain and fatigue: accuracy of ratings across different reporting periods. Qual Life Res 2010; 19: 1163-1170.
11. Wood WA, Deal AM, Bennett AV, et al. Comparison of seven-day and repeated 24-hour recall of symptoms in the first 100 days after hematopoietic cell transplantation. J Pain Symptom Manage 2015; 49: 513-520.
12. Dueck AC, Mendoza TR, Mitchell SA, et al.; National Cancer Institute PRO-CTCAE Study Group. Validity and reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). JAMA Oncol 2015; 1: 1051-1059.
13. Reeve BB, Mitchell SA, Dueck AC, et al. Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials. J Natl Cancer Inst 2014; 106. DOI: 10.1093/jnci/dju129.
14. Bennett AV, Dueck AC, Mitchell SA, et al.; National Cancer Institute PRO-CTCAE Study Group. Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Health Qual Life Outcomes 2016; 14: 24.
15. Dunlap WP, Cortina JM, Vaslow JB, et al. Meta-analysis of experiments with matched groups or repeated measures designs. Psychol Methods 1996; 1: 170-177.
16. Cohen J., Statistical power analysis for the behavioral sciences. 2nd ed. New York: Routledge, 1988.
17. Shrout PE, Fleiss JL., Intraclass correlations: uses in assessing rater reliability. Psychol Bull 1979; 86: 420-428.
18. Norquist JM, Girman C, Fehnel S, et al. Choice of recall period for patient-reported outcome (PRO) measures: criteria for consideration. Qual Life Res 2012; 21: 1013-1020.